MitrAssist offers a minimally invasive approach to mitral regurgitation treatment.
MitrAssist has raised $100.0M in total funding. The most recent round was Series C. The last funding was announced in September 2023.
MitrAssist's investors include Centurium Capital, CITIC Capital Holdings, 6 Dimensions Capital, Fosun International, Fosun Pharma.
MitrAssist is headquartered in Misgav Dov, Israel.
MitrAssist offers a minimally invasive approach to mitral regurgitation treatment.
MitrAssist is at the Series C stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"MitrAssist — Funding & Investors." VCBacked, September 26, 2023, https://www.vcbacked.co/company/mitrassist. Accessed July 22, 2026.
VCBacked. (2023). MitrAssist — Funding & Investors. Retrieved July 22, 2026, from https://www.vcbacked.co/company/mitrassist
{{cite web |title=MitrAssist — Funding & Investors |url=https://www.vcbacked.co/company/mitrassist |website=VCBacked |access-date=July 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated